KR101862742B1 - Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same - Google Patents
Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same Download PDFInfo
- Publication number
- KR101862742B1 KR101862742B1 KR1020170149617A KR20170149617A KR101862742B1 KR 101862742 B1 KR101862742 B1 KR 101862742B1 KR 1020170149617 A KR1020170149617 A KR 1020170149617A KR 20170149617 A KR20170149617 A KR 20170149617A KR 101862742 B1 KR101862742 B1 KR 101862742B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- water
- gastritis
- jade
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 11
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims description 52
- 230000006872 improvement Effects 0.000 title description 11
- 230000002265 prevention Effects 0.000 title description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000010977 jade Substances 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 41
- 208000007882 Gastritis Diseases 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 32
- 229920002670 Fructan Polymers 0.000 claims abstract description 21
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 16
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims abstract description 16
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000001704 evaporation Methods 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 238000007710 freezing Methods 0.000 claims abstract description 7
- 230000008014 freezing Effects 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 238000005507 spraying Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 208000000689 peptic esophagitis Diseases 0.000 claims description 36
- 241000196324 Embryophyta Species 0.000 claims description 31
- 238000000855 fermentation Methods 0.000 claims description 21
- 230000004151 fermentation Effects 0.000 claims description 21
- 206010057969 Reflux gastritis Diseases 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 11
- 240000006927 Foeniculum vulgare Species 0.000 claims description 8
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 241000332371 Abutilon x hybridum Species 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 241000257303 Hymenoptera Species 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 241001070941 Castanea Species 0.000 claims description 3
- 235000014036 Castanea Nutrition 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 244000300264 Spinacia oleracea Species 0.000 claims description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000010802 sludge Substances 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 14
- 239000011707 mineral Substances 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 206010030216 Oesophagitis Diseases 0.000 abstract 3
- 208000006881 esophagitis Diseases 0.000 abstract 3
- 230000011514 reflex Effects 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 2
- 238000000227 grinding Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 235000010755 mineral Nutrition 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 8
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 8
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000006549 dyspepsia Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000034656 Contusions Diseases 0.000 description 5
- 241000123069 Ocyurus chrysurus Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000034526 bruise Diseases 0.000 description 5
- 208000024798 heartburn Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000131482 Bifidobacterium sp. Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241001627205 Leuconostoc sp. Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001180649 Myrcia group Species 0.000 description 2
- GKXJWSZPLIKUPS-IUNAMMOKSA-N N-[(2Z,6Z)-2,6-bis(hydroxyimino)cyclohexylidene]hydroxylamine Chemical compound O\N=C1\CCC\C(=N\O)C1=NO GKXJWSZPLIKUPS-IUNAMMOKSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000554910 Pulsatilla cernua var. koreana Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194022 Streptococcus sp. Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003673 groundwater Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- -1 inulin carbohydrates Chemical class 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241001083548 Anemone Species 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000007217 Esophageal Stenosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000604136 Pediococcus sp. Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002905 effect on arthritis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940039506 mylanta Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940108322 zantac Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 역류성 식도염 및 위염 개선 및 예방용 조성물 및 그의 제조방법에 관한 것이다. The present invention relates to a composition for improving and preventing reflux esophagitis and gastritis, and a method for producing the same.
역류성 식도염(GRD: gastroesophageal reflux disease)은 유럽이나 미국과 같은 서구에서는 오래 전부터 흔한 질환이었는데 최근 식생활이나 생활습관의 서구화에 따라 우리 나라에서도 점차 증가하고 있다.Gastroesophageal reflux disease (GRD) has been a long-standing disease in western countries such as Europe and the United States, but has recently been increasing in Korea as well, due to Westernization of diet and lifestyle.
가슴앓이가 가장 흔한 역류성 식도염의 증상이다. 이는 대개 명치 끝에서 목구멍 쪽으로 치밀어 오르는 듯한 타는 통증, 화끈거림, 쓰라린 느낌 또는 불쾌감을 말한다. 이 증상은 등이나 목 쪽으로 뻗칠 수 있으며 음식을 삼키기 어렵다고 느끼는 연하곤란과 함께 나타날 수 있다.Heartburn is the most common symptom of reflux esophagitis. It usually refers to burning pain, burning, bitterness, or discomfort that seems to climb from the end of the stomach to the throat. This symptom can be spread to the back or neck and can be accompanied by dysphagia, which feels difficult to swallow.
산 역류도 중요한 증상인데 이는 신물이나 쓴물 혹은 소화된 음식물이 다시 입으로 넘어 오는 것을 말한다. 때로는 가슴이 아프거나 음식이 걸리는 느낌이 발생되기도 하고 음식을 먹지 않을 때에도 목에 덩어리가 있다고 느끼기도 한다. 상복부(오목가슴)의 반복적인 통증이나 불편감 혹은 만성적인 기침도 역류성 식도염의 증상일 수 있다.Acid reflux is also an important symptom, which means that sickness, bitterness, or digestive food come back into your mouth. Sometimes the chest feels sick or hungry, and even when you do not eat, you may feel lumps in your neck. Repetitive pain or discomfort in the upper abdomen (concave chest) or chronic cough may also be a symptom of reflux esophagitis.
역류성 식도염의 가슴 앓이는 하루 중 언제나 생길 수 있지만 주로 식사 후 혹은 누운 자세에서 심해지는 것이 중요한 특징이다. 흔히 속쓰림과 혼동되기도 하는데 이는 기능성 소화불량이나 위궤양 혹은 십이지장 궤양에서보다 자주 나타나는 증상으로 식사 전 즉 속이 비었을때 상복부(오목가슴)의 증상이 심해지는 경향이 있다. 따라서 역류성 식도염의 증상과 속쓰림은 매우 비슷하지만 그 위치와 발생하는 시간에 다소 차이가 있다.Heartburn in reflux esophagitis can occur any time of the day, but it is important to get worse after eating or lying down. It is often confused with heartburn, which is a more common symptom of functional dyspepsia or gastric ulcer or duodenal ulcer, which tends to increase the symptoms of the upper abdomen (the concave chest) before the meal is empty. Symptoms of reflux esophagitis and heartburn are very similar, but there is a slight difference in their location and time.
이 질환의 가장 큰 문제는 증상이 한번 생기면 대개 만성적으로 발전해 삶의 질을 떨어뜨릴 수 있다는 것이다. 즉, 목 이물감이 지속되면 만성 기침은 물론 이를 분해하기 위해 세균이 작용하며 구취가 발생해 단체생활에 지장을 받기도 하고, 누워있을 때 주로 증상이 생기기 때문에 가슴이 답답해 숙면을 취하기 어렵다. 또한 역류성 식도염의 경우, 방치하면 드물지만 식도협착이나 식도암 등으로 발전할 수도 있다. 따라서 증상이 느껴지면 병원을 찾아 정확한 진단을 받고 치료를 하는 것이 무엇보다 중요하다. 특히, 단순히 위산을 억제하는 약물치료는 약을 중단하거나 용량을 줄이면 증상이 재발하는 경우가 많아 근본적인 치료와 식이조절이 필요하다.The biggest problem with this disease is that once it is symptomatic, it usually develops chronically and can reduce the quality of life. In other words, if the foreign body of the neck persists, the chronic cough, as well as bacteria act to decompose it, and it is difficult to take a good night's sleep because the bad breath is caused by bad breath and the symptom occurs mainly when lying down. In the case of reflux esophagitis, it is rare to leave, but it may develop into esophageal stricture or esophageal cancer. Therefore, if you feel any symptoms, it is important to find a hospital and get the correct diagnosis and treatment. In particular, drug therapy that simply suppresses gastric acid requires frequent treatment and dietary control because of the frequent recurrence of symptoms when the drug is discontinued or the dose is reduced.
역류성 식도염의 치료에는 위산의 분비를 억제하는 여러 가지 약제가 사용되며, 가장 흔히 처방되는 약제는 오메프라졸이나 라베프라졸과 같은 수소펌프 억제제이다 이는 위산의 분비를 90% 이상 줄임으로써 비록 역류가 계속 일어나더라도 증상이 발생하지 않고 식도의 병변이 진행하는 것을 막아준다. 식도와 하부식도 괄약근의 운동성을 조절하는 약들도 사용되고 있으며, 위의 약제를 함께 사용하는 경우도 있다. 잔탁(Zantac), 마일란타(Mylanta)같은 약물을 사용하여 위산의 분비를 억제하거나 위산 위에 막을 씌워 위산이 올라오더라도 그 막이 식도를 미리 감싸 염증을 가라앉힌다. 염증 질환이라고 비스테로이드성 항염제 (Non-steroidal Antiinflammatory Drugs)를 사용하면 해당 항염제에 있는 위산분비 효과로 인해 속쓰림 등의 생길 수 있다. 아스피린, 부루펜(ibuprofen) 등의 약이 이에 속한다.In the treatment of reflux esophagitis, various drugs are used to inhibit the secretion of gastric acid. The most commonly prescribed drugs are hydrogen pump inhibitors such as omeprazole and rabeprazole, which reduce gastric acid secretion by more than 90% Even if the symptoms do not occur, it prevents esophageal lesions from progressing. Drugs that control the motility of the esophagus and lower esophageal sphincter are also used, and some of the above medications may be used together. Zantac and Mylanta are used to inhibit the secretion of gastric acid or put a film on the stomach acid, even if the stomach acid up the membrane of the esophagus is wrapped around the inflammation. The use of non-steroidal antiinflammatory drugs (NSAIDs), which are inflammatory diseases, can cause heartburn due to gastric acid secretion in the corresponding anti-inflammatory drugs. Aspirin, and ibuprofen.
위의 여러 방법으로도 증상의 호전이 없는 경우에는 수술을 권유 받게 된다. 몇 가지 합병증이 생겨서 수술을 받는 경우도 있지만 이런 경우는 매우 드문 편이다. 최근에는 배나 가슴을 열지 않고 복강경을 이용한 수술법이 개발되어 있다.If the symptoms are not improved by any of the above methods, surgery is recommended. Some complications have occurred and some have undergone surgery, but this is rare. Recently, laparoscopic surgery has been developed without opening the abdomen or the chest.
그러나, 상기와 같은 화학합성 약물치료는 장기간 치료시에 인체에 좋지 않은 영향을 끼칠 수 있으며, 수술요법은 환자에게 큰 부담을 주며, 효과도 탁월하지 않은 단점이 있다.However, the chemo-synthetic drug treatment as described above may adversely affect the human body during long-term treatment, and the surgical treatment is a burden on the patient, and the effect is not excellent.
그러므로, 화학합성 약물치료와 수술요법과 외에 천연성분을 활용하여 역류성 식도염을 개선 및 예방할 수 있는 방법의 개발이 요구되고 있다. Therefore, there is a need to develop a method for improving and preventing reflux esophagitis by using natural ingredients besides chemical synthetic drug therapy and surgical therapy.
본 발명은, 종래기술의 상기와 같은 단점을 해결하기 위하여 안출된 것으로서,SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned disadvantages of the prior art,
천연성분인 옥분말, 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 미넬랄, 로진, 프럭탄 및 식물발효 효소액을 사용하여, 역류성 식도염 및 위염을 부작용 없이 효과적으로 개선 및 예방할 수 있는 역류성 식도염 및 위염 개선 및 예방용 조성물 및 그의 제조방법을 제공하는 것을 목적으로 한다. Reflux esophagitis and gastritis can be effectively used without side effects by using natural alkaline reducing water, minerals, rosin, fructans and plant fermentation enzyme solution, which are collected from the natural ingredients such as jade powder and jade mines, And a composition for improving and preventing gastritis and a process for producing the same.
본 발명은, 상기 목적을 달성하기 위하여, The present invention, in order to achieve the above object,
옥분말, 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수에 포함된 미네랄, 로진, 프럭탄(Fructan) 및 식물발효 효소액을 포함하며,Rosin, fructan, and vegetable fermentation enzyme solution contained in natural alkaline reducing water of pH 7.5 to 8.5, which is collected from the jade powder and jade mine area,
(a) 평균입자크기가 100 ∼ 300 메쉬인 옥분말 3~7 중량부, 로진 2~5 중량부, 프럭탄(Fructan) 2~5 중량부를 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 50~100 중량부에 혼합하는 단계; (a) 3 to 7 parts by weight of jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말에 넣어 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물을 제공한다. (e) coating the surface of the ground particles prepared in the step (d) with a powder of jade powder having an average particle size of 100 to 300 mesh to improve reflux esophagitis and gastritis. ≪ / RTI >
상기 옥분말은 연옥분말일 수 있다. The jade powder may be a nephrite powder.
상기 식물발효 효소액은The plant fermentation enzyme solution
(ⅰ) 개별꽃 1~10 중량부, 은행 1~20 중량부, 고련피 1~10 중량부, 도라지 1~20 중량부, 금전초 1~10 중량부, 더덕 1~20 중량부, 꼭두서니 1~10 중량부, 할미꽃 1~10 중량부, 흰목이버섯 1~10 중량부, 잔대 1~20 중량부, 으름 1~20 중량부, 수염가래꽃 1~10 중량부, 움나무 1~20 중량부 및 그라비올라 잎 1~20 중량부를 포함하는 약초 식물을 씻어 물을 빼는 단계; (I) 1 to 10 parts by weight of an individual flower, 1 to 20 parts by weight of a bank, 1 to 10 parts by weight of spinach, 1 to 20 parts by weight of bellflower, 1 to 10 parts by weight of fennel, 1 to 20 parts by weight of fennel, 1 to 10 parts by weight of hymenoptera, 1 to 10 parts by weight of white chestnut mushroom, 1 to 20 parts by weight of cornstarch, 1 to 20 parts by weight of crumbs, 1 to 10 parts by weight of bean sprout flowers, 1 to 20 parts by weight And 1 to 20 parts by weight of graviola leaves;
(ⅱ) 상기 (ⅰ)단계에서 씻은 약초 식물을 항아리에 넣고, 미생물의 먹이가 될 수 있는 당을 상기 식물 100 중량부를 기준으로 10~30 중량부로 넣고, 젖산균 및 효모 중의 1종 이상의 균주를 접종하여 20~40℃에서 1~4개월 동안 발효시키는 단계;(Ii) The herbaceous plant washed in step (i) is placed in a jar and 10 to 30 parts by weight of sugar capable of being fed to the microorganism is added in an amount of 10 to 30 parts by weight based on 100 parts by weight of the plant and one or more strains of lactic acid bacteria and yeast are inoculated Followed by fermentation at 20 to 40 ° C for 1 to 4 months;
(ⅲ) 발효된 찌꺼기를 걸러서 짜낸 후, 1~10개월 숙성시키는 단계;를 포함하는 방법에 의해 제조되는 것일 수 있다. (Iii) squeezing out the fermented debris and squeezing for 1 to 10 months.
상기 역류성 식도염 및 위염 개선 및 예방용 조성물은 건강기능성식품일 수 있다. The composition for improving and preventing gastroesophageal reflux and gastritis may be a health functional food.
본 발명은 또한, The present invention also relates to
(a) 평균입자크기가 100 ∼ 300 메쉬인 옥분말 3~7 중량부, 로진 2~5 중량부, 프럭탄(Fructan) 2~5 중량부를 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 50~100 중량부에 혼합하는 단계; (a) 3 to 7 parts by weight of jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말과 혼합하여 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물의 제조방법을 제공한다.(e) mixing the crushed particles prepared in the step (d) with a jade powder having an average particle size of 100 to 300 mesh, and coating the jade powder on the surface. The present invention also provides a method of preparing a composition for preventing such a disease.
본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물은 천연성분인 옥분말, 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 미넬랄, 로진, 프럭탄 및 식물발효 효소액을 사용하여 제조되므로, 역류성 식도염 및 위염 증상을 갖고 있는 사람이 부담 없이 복용할 수 있으며, 부작용 염려가 없으며, 효과적으로 역류성 식도염 및 위염 증상을 개선 및 예방하는 효과를 제공한다.Since the composition for improving and preventing gastroesophageal reflux and gastritis according to the present invention is prepared using a natural alkaline-reduced water having a pH of 7.5 to 8.5, rosin, fructan, and a plant fermentation enzyme, It can be taken easily by people with reflux esophagitis and gastritis, has no side effects, and has the effect of effectively improving and preventing reflux esophagitis and gastritis.
도 1은 시험예 2의 급성 역류성식도염 모델에서의 식도 조직 손상도를 비교하여 나타낸 것이,
도 2는 시험예 2의 급성 역류성식도염 모델에서의 조직병리학적 검사 결과를 나타낸 것이며,
도 3은 시험예 2의 식도 조직에서의 iNOS 발현량을 측정한 결과를 나타낸 것이며,
도 4는 시험예 3의 급성 위염 모델에서의 위 조직 손상도를 비교하여 나타낸 것이며,
도 5는 시험예 3의 급성 위염 모델에서의 조직병리학적 검사결과를 나타낸 것이며,
도 6은 시험예 3의 위 조직에서의 iNOS 발현량을 측정한 결과를 나타낸 것이며,
도 7 내지 31은 시험예 4의 임상시험결과로서 시험에 참여한 개별 참여자의 평가결과(7 내지 30), 식도촬영결과, 및 종합평가결과(31)를 나타낸 것이다.Fig. 1 shows a comparison of esophageal tissue damage in the acute reflux esophagitis model of Test Example 2,
Fig. 2 shows the histopathological examination results in the acute reflux esophagitis model of Test Example 2,
Fig. 3 shows the results of measuring the amount of iNOS expression in the esophageal tissue of Test Example 2,
Fig. 4 shows a comparison of gastric tissue damage in the acute gastritis model of Test Example 3,
FIG. 5 shows the results of histopathological examination in the acute gastritis model of Test Example 3,
Fig. 6 shows the results of measuring the amount of iNOS expression in the stomach tissue of Test Example 3,
Figs. 7 to 31 show the evaluation results (7 to 30), the esophageal photographing results, and the comprehensive evaluation results (31) of individual participants participating in the test as the clinical test results of Test Example 4.
이하에서 본 발명의 바람직한 실시예를 첨부된 도면을 참고하여 설명한다. 본 발명의 상세한 설명에 앞서, 이하에서 설명되는 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 된다. 따라서, 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings. Prior to the description of the present invention, terms and words used in the present specification and claims to be described below should not be construed as limited to ordinary or dictionary terms. Therefore, the embodiments described in this specification and the configurations shown in the drawings are merely the most preferred embodiments of the present invention and do not represent all the technical ideas of the present invention. Therefore, It is to be understood that equivalents and modifications are possible.
본 발명은 옥분말, 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수에 포함된 미네랄, 로진, 프럭탄(Fructan) 및 식물발효 효소액을 포함하며,The present invention includes minerals, rosins, fructans and plant fermentation enzyme solutions contained in natural alkaline-reduced water having a pH of 7.5 to 8.5,
(a) 평균입자크기가 100 ∼ 300 메쉬인 옥분말 3~7 중량부, 로진 2~5 중량부, 프럭탄(Fructan) 2~5 중량부를 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 50~100 중량부에 혼합하는 단계; (a) 3 to 7 parts by weight of jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말에 넣어 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물에 관한 것이다.(e) coating the surface of the ground particles prepared in the step (d) with a powder of jade powder having an average particle size of 100 to 300 mesh to improve reflux esophagitis and gastritis. ≪ / RTI >
상기 옥분말로는 연옥분말이 바람직하게 사용될 수 있다. As the above-mentioned octane powder, a nephrite powder may be preferably used.
신농본초, 본초강목에 의하면 얼굴, 몸 등에 상처자국이 있을 때 연옥분말로 상처 부위를 수일간 문지르면 흉터가 없어지며 피부를 윤택하게 해주는 등 연옥의 주성분은 인체의 각 요소와 일치하여 부작용이 없이 인체에 탁월한 효능을 발휘하는 것으로 알려져 있다.When the wound is scratched for several days with a nephrite powder, the main component of the nephrite is consistent with each element of the body, such as scars disappear and the skin is enriched. Is known to exert excellent efficacy.
옥이 내는 원적외선은 인체의 혈액 순환을 왕성하게 하고 몸 속을 따뜻하게 열을 가해 주기 때문에 각종 성인병 예방에도 효과가 있다. 또한, 상기 원적외선은 치약 중의 다른 성분들의 활성을 극대화시키는 기능을 수행한다.The far-infrared rays inside the jade are effective for prevention of various adult diseases because the blood circulation of the body is energized and the heat is applied to the inside of the body. Further, the far-infrared rays function to maximize the activity of other components in the toothpaste.
동의보감에 의하면 옥가루를 깨알만하게 만들어 복용하면 오장육부를 윤택하게 하고 체내에 노폐물을 배출시켜 주며 위장의 열을 제거해 소화계통에 효과가 있으며, 또한 옥가루를 장복하면 몸이 날아갈 듯 가벼워지고 폐장의 기능을 윤활하게 해주며 성대의 발성을 도와주고 인후에 좋은 것으로 기술되어 있다. According to Donguibogam, it makes the corn germs softer and makes the corn germs more radiant, expels waste in the body, eliminates the heat of the stomach and is effective in the digestive system. Also, when the corn is ingested, it becomes lighter and easier. It lubricates, helps the voice of the vocal cords, and is described as good for the throat.
상기 연옥분말은 채광 시나 보석 세가공시에 파생되는 잔재 물 또는 폐기물로 처리되는 연옥을 사용하여 제조할 수 있어 바람직하다. It is preferable that the nephrite powder can be produced by using nephrite treated with remnants or wastes derived from mines or gemstones.
상기 연옥분말의 평균입자크기는 100 ∼ 300 메쉬인 것이 사용될 수 있다. The average particle size of the nephrite powder may be 100 to 300 mesh.
본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물은 상기 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수(일명, '옥정수')를 사용하여 제조되는 것을 특징을 갖는다. 즉, 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수를 첨가하고 순수 물 성분을 모두 증발시킴으로써 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수에 포함된 무기질 및 미네랄 등의 유익한 성분이 제조되는 역류성 식도염 및 위염 개선 및 예방용 조성물에 모두 포함될 수 있게 하는 특징을 갖는다. The composition for improving and preventing gastroesophageal reflux and gastritis according to the present invention is characterized in that it is prepared using natural alkaline reducing water (also called 'corn oil') having a pH of 7.5 to 8.5, which is collected in the above-mentioned jade mine area. In other words, by adding the natural alkaline reducing water of pH 7.5 ~ 8.5 collected in the jade mine area and evaporating all pure water components, beneficial components such as minerals and minerals contained in the natural alkaline reducing water of pH 7.5-8.5 Can be included both in the reflux esophagitis and gastritis improving and preventing composition to be produced.
옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수로는 옥광산 지역에서 생산되는 지하수가 사용될 수 있다. 상기 옥광산 지역에서 생산되는 지하수는 물의 성질이 온순하고 맛이 달며 깨끗해서 독이 없는 특징을 갖는다(동의보감). 또한, 사람들이 오랫동안 먹으면 오장육부가 윤택해지고 체내의 노폐물이 빠져나가며, 머리털이 희어지지 않는다고 한다(본초강목). 중국 사람들은 예로부터 옥을 귀하게 여겨 늘 몸에 지지고 다니는 것으로 알려졌는데, 이는 인체에 직접적인 영향을 미쳐서 신경을 안정시키고 오장육부의 기능 강화에 효과가 있기 때문이라고 한다. Groundwater produced in the Jade Mine area can be used as the natural alkaline water of pH 7.5 ~ 8.5 collected from the Jade mine area. The groundwater produced in the Jade Mine area is characterized by the mild nature of the water, its taste, and its clean nature. In addition, when people eat for a long time, the five-legged meat becomes rich, the waste in the body escapes, and the hair is not whitened. It is said that Chinese people have always been prone to jade because they have been directly influenced by the human body, stabilizing the nervous system and strengthening the functions of the five muscles.
천연 알칼리환원수는 전세계적으로 희귀한 물로 학계에 조차 잘 알려져 있지 않은 물이다. 국내 혹은 일본에서도 알칼리환원수라 하면 보통 이온수기를 통해 만들어진 알칼리수로 구분한다. 알칼리수는 만성설사, 위염, 위산과다, 소화불량, 위장내 이상발효, 변비, 피로감해소, 감기예방, 식욕부진 회복, 고혈압, 당뇨, 알레르기, 류머티즘, 과음숙취해소, 천식, 두드러기에 효과가 있다.Natural Alkali Reduced Water is water that is rarely known even in academia because it is rare in the world. In Korea or Japan, alkaline water is usually divided into alkaline water, which is produced by ionized water. Alkaline water is effective in chronic diarrhea, gastritis, gastric hyperplasia, dyspepsia, abnormal gastric fermentation, constipation, relieving fatigue, preventing colds, restoring appetite, hypertension, diabetes, allergies, rheumatism, relieving hangover, asthma and urticaria.
본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물의 제조에는 상기 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수가 사용되는 것이 가장 바람직하다. 그러나, 천연 pH 7.5~8.5의 천연 알칼리환원수라면 본 발명에 사용될 수도 있다. It is most preferred that the natural alkaline reducing water having a pH of 7.5 to 8.5 collected from the above-mentioned jade mine area is used for preparing the composition for improving and preventing gastroesophageal reflux and gastritis of the present invention. However, natural alkaline reducing water having a natural pH of 7.5 to 8.5 may be used in the present invention.
상기에서 천연 알칼리환원수는 pH가 8.0~8.5인 것이 더욱 바람직하다.The pH of the natural alkali reduced water is more preferably 8.0 to 8.5.
상기 로진은 약용성분으로서 천연 알칼리환원수에서 추출된 미네랄과 옥분말을 결합시키는 역할을 한다. 로진은 '송진'이라고도 불린다.The rosin acts as a medicinal component to bind the jute powder with the minerals extracted from the natural alkali reduced water. Rosin is also called 'rosin'.
송진은 맛이 쓰고 달며, 본성은 따뜻하고 독이 없다. 오장을 편하게 하고 열을 제거하며 풍비(風痺)와 사기(死肌)를 다스리고, 모든 악창, 두비(頭痺), 백독(白禿), 개소(疥瘙)를 주치하고, 이농(耳濃)과 치아의 풍치로 인한 구멍을 다스리고 모든 창에 붙이면 피부가 생하고 통증이 그치고, 충을 죽인다. 일명 송고 또는 송지라 한다. 6월에 스스로 흘러 나오는 것을 취하는 것이 굳은 것을 따거나 혹은 달여서 취한 것 보다 낫고 통명(通明)하여서 훈육향(勳陸香)과 같은 것이 좋다. <동의보감> Songjin is tasty and sweet, nature is warm and poisonous. It relaxes the mind, removes the heat, governs the wind and the dead skin, and treats all the males, head pals, white fur, and spot fur, ) And the taste of the teeth, and attaches it to all the windows, the skin is born, the pain stops, and it kills the insect. It is called a song or song. It is better to take things that come out in June than to take hard ones or to be better than the ones that have been taken from the moon, and that is the same as the discipline incense. <Dongbu Bang>
송진은 예로부터 민간요법에서 종기, 부스럼, 담, 가슴 결리는 데, 타박상, 유암, 치통, 풍치, 치담, 칼에 베인 데, 철독, 버짐, 거담, 폐결핵, 폐렴, 돼지에 물린 데, 위장병, 외상 등을 치유하는데 사용했다. Songjin has been suffering from bruise, bruise, fainting, bruise, bruise, fatigue, toothache, flavor, chidamen, calvaine, insomnia, ringworm, genomes, pulmonary tuberculosis, pneumonia, It was used to heal the back.
송진은 곧 장근골, 치어혈, 소염, 소종, 소창, 살충하며, 눈을 밝게 하여 주고, 썩은 살을 제거하는 동시에 새살이 나오게 하는 약리적 작용을 한다. Songjin is a pharmacologic effect that immediately causes stigmata, petechiae, inflammation, scurvy, scalding, insecting, brightening eyes, eliminating rotten flesh and bringing out new life.
상기 프럭탄(Fructan)은 식이섬유로서 천연 알칼리환원수에서 추출된 미네랄과 옥분말을 결합시키는 역할을 한다. 프럭탄은 과당으로 이루어진 다당체이다. 프럭탄은 과당으로 이루어진 중합체로 섭취 시 체내에서 비만 예방, 미네랄 흡수 촉진, 장내유산균 생육 촉진 기능을 수행한다. 또한 식물체와 미생물에서 발견되는 천연물질로 수천~수만개의 과당으로 이루어진 바이오폴리머로서 우리의 대표적인 전통 음식인 청국장과 건강에 좋은 것으로 알려진 호박, 양파, 마늘 등과 생명력이 강한 보리, 선인장, 목초와 같은 식물체에 포함되어 있다.The fructan is a dietary fiber and serves to bind the minerals extracted from the natural alkali reduced water with the jade powder. Fructans are polysaccharides composed of fructose. Fructan is a polymer composed of fructose, and when ingested, it functions to prevent obesity, promote mineral absorption, and stimulate the growth of lactic acid bacteria in the intestines. It is a biomolecule composed of thousands to tens of thousands of fructose, a natural substance found in plants and microorganisms. It is a biopolymer of our representative traditional food such as chungkukjang, amber, onion, and garlic which are known to be good for health, and plants such as barley, cactus, .
프럭탄은 주로 프럭토스 단위로 이루어져 있고 프럭토실-프럭토스 결합이 그 결합의 대부분을 이루는 탄수화물 사슬로 이루어져 있다. 프럭럭탄은 통상 다분산 탄수화물로서 생성된다. 이들은 식물에서 존재하지만, 세균 활성으로부터 비롯될 수도 있고 효소적으로도 합성될 수 있다.Fructans consist mainly of fructose units and fructose-fructose bonds consist of carbohydrate chains that make up the majority of the bonds. Fructans are usually produced as polydisperse carbohydrates. They are present in plants, but they can originate from bacterial activity and can also be enzymatically synthesized.
프럭탄은 레반 및 이눌린 탄수화물을 포함하는 것으로서 잘 공지되어 있는 화합물이다. 레반은 대개 서로 β(2-6) 결합으로 연결된 것을 주로하는 프럭토스 단위 사슬로 이루어진 D-프럭토스이다. 이눌린은 개 프럭토스 단위로 이루어져 있지만 서로 β(2-1) 결합으로도 연결된 것을 주로 한다. 대부분의 이눌린은 한 글루코스 단위에서 종결된다.Fructans are well known compounds including levan and inulin carbohydrates. Levan is a D-fructose consisting of a fructose unit chain predominantly linked to each other by β (2-6) bonds. Inulin is made up of difunctional units, but they are also linked to each other by β (2-1) bonds. Most inulin is terminated in one glucose unit.
프럭탄, 특히 이눌린은 혈액 콜레스테롤 및 혈청 트리글리세리드량에 저하 효과를 끼치고 HDL/LDL 비에 증가 효과를 끼치는 것을 비롯하여 지질 대사에 유익한 영향을 끼치는 것으로도 알려져 있다.Fructans, particularly inulin, are also known to have beneficial effects on lipid metabolism, including lowering blood cholesterol and serum triglycerides and increasing HDL / LDL ratios.
피.디.쿠퍼(P.D.Cooper) 등의 문헌[Molecul. Immunol., 23(8), 895, (1986)]에서는 감마-이눌린에 의한 보체 활성화의 또다른 경로가 기재되어 있고, 보체의 또다른 경로 중의 활성인자가 잠재적 비특이적 항종양 효과를 가지는 것으로 알려져 있다. 또한, 프럭탄, 특히 이눌린은 암의 예방 및 치료에 가능성이 있는 것으로 기재되어 있다. 피.디.쿠퍼 등의 문헌[Molecul. Immunol., 23(8), 895, (1986)]에서는 복강내 주사된 감마-이눌린이 흑색종을 갖는 생쥐의 생존을 연장할 수 있는 것으로 보고되었다.P.D. Cooper et al., Molecul. Immunol., 23 (8), 895, (1986)) describes another pathway of gamma-inulin-dependent complement activation and that other active pathways in the complement pathway have potential non-specific antitumor effects . In addition, fructans, in particular inulin, have been described as potentially for the prevention and treatment of cancer. P. D. Cooper et al., Molecul. Immunol., 23 (8), 895, (1986)], it has been reported that gamma-inulin administered intraperitoneally can prolong the survival of melanoma-bearing mice.
본 발명에서 상기 식물발효 효소액은In the present invention, the plant fermentation enzyme solution
(ⅰ) 개별꽃 1~10 중량부, 은행 1~20 중량부, 고련피 1~10 중량부, 도라지 1~20 중량부, 금전초 1~10 중량부, 더덕 1~20 중량부, 꼭두서니 1~10 중량부, 할미꽃 1~10 중량부, 흰목이버섯 1~10 중량부, 잔대 1~20 중량부, 으름 1~20 중량부, 수염가래꽃 1~10 중량부, 움나무 1~20 중량부 및 그라비올라 잎 1~20 중량부를 포함하는 약초 식물을 씻어 물을 빼는 단계; (I) 1 to 10 parts by weight of an individual flower, 1 to 20 parts by weight of a bank, 1 to 10 parts by weight of spinach, 1 to 20 parts by weight of bellflower, 1 to 10 parts by weight of fennel, 1 to 20 parts by weight of fennel, 1 to 10 parts by weight of hymenoptera, 1 to 10 parts by weight of white chestnut mushroom, 1 to 20 parts by weight of cornstarch, 1 to 20 parts by weight of crumbs, 1 to 10 parts by weight of bean sprout flowers, 1 to 20 parts by weight And 1 to 20 parts by weight of graviola leaves;
(ⅱ) 상기 (ⅰ)단계에서 씻은 약초 식물을 항아리에 넣고, 미생물의 먹이가 될 수 있는 당을 상기 식물 100 중량부를 기준으로 10~30 중량부로 넣고, 젖산균 및 효모 중의 1종 이상의 균주를 접종하여 20~40℃에서 1~4개월 동안 발효시키는 단계;(Ii) The herbaceous plant washed in step (i) is placed in a jar and 10 to 30 parts by weight of sugar capable of being fed to the microorganism is added in an amount of 10 to 30 parts by weight based on 100 parts by weight of the plant and one or more strains of lactic acid bacteria and yeast are inoculated Followed by fermentation at 20 to 40 ° C for 1 to 4 months;
(ⅲ) 발효된 찌꺼기를 걸러서 짜낸 후, 1~10개월 숙성시키는 단계;를 포함하는 방법에 의해 제조되는 것을 특징으로 한다. (Iii) squeezing out the fermented debris and squeezing for 1 to 10 months.
상기 개별꽃은 민간에서 기를 보충하고 위장을 튼튼하게 하며 양기를 좋게 하는 보약으로 더러 쓴다. 맛은 달고 약간 쓰며 성질은 평하다. 폐와 위를 튼튼하게 하고 진액을 늘려준다. 병을 앓고 나서 허약한 사람이나 몸이 약한 어린이, 노인들이 먹으면 몸이 튼튼해진다고 한다. 개별꽃은 인삼과 효력이 비슷한데 인삼을 먹을 때 나타날 수 있는 부작용이 나타나지 않는다.The individual flowers are used by the private to supplement the stomach, to strengthen the stomach, and to improve the yang. The taste is sweet, a little bit worn, and the quality is plain. Lengthen the lungs and stomach, and increase the amount of essence. After suffering from sickness, people who are frail, weak children or elderly people are said to be strong. Individual flowers are similar in effect to ginseng, and there are no side effects that can occur when ginseng is eaten.
개별꽃은 정신적 피로, 저절로 담이 나는 증상, 건망증, 불면증, 입맛 없는데, 입 안이 마를 때, 가슴이 두근거릴 때 등에 약으로 쓴다.Individual flowers are mental fatigue, self-indulgent symptoms, amnesia, insomnia, no appetite, and when I drink inside my mouth, when my chest is throbbing.
고련피는 한의학에서 생약으로 사용되고 있는 약용식물로서 다양한 생리활성물질을 함유하고 있다. 고련피는 멀구슬 나무과(Meliaceae)에 속한 낙엽교목인 멀구슬나무(Melia azedarach Linne var. japonica Makino)의 수피 또는 근피로서 한의학에서 풍진, 악창, 옴, 나병, 고열, 피부습진, 이뇨, 지양, 이수, 부인과 질환 및 질염을 치료하기 위해 사용되었다. 또한 약리작용으로 살충, 해열작용, 촌충 또는 회중제거(항기생충 효과) 및 트리코모나스 질염(항원충 효과)에 효과가 있음이 보고되었다.It is a medicinal plant used as a herbal medicine in Oriental medicine and contains various physiologically active substances. The bark of Melia azedarach Linne var. Japonica Makino, a deciduous tree belonging to Meliaceae, is a bark or muscle in Oriental medicine. It is caused by rubella, malaria, leprosy, leprosy, fever, skin eczema, diuretic, , Gynecological diseases and vaginitis. It has also been reported that pharmacological actions are effective in insecticidal action, antipyretic action, tapeworm or concretion elimination (antiparasitic effect) and trichomonas vaginitis (antigenic effect).
상기 금전초(병꽃풀)는 당뇨병, 중이염, 간염, 기관지염 담낭결석, 신장결석, 천식 등온갖 질병에 두루 효험이 있는 만능의 약초이다. 금전초를 우리말로는 긴병꽃풀이라고 부른다. 우리나라 어디에서나 자라는데 대개 물기 많고 햇볕이 잘 드는 양지 쪽에 흔하다.The fungus is a universal herb that is efficacious in diseases such as diabetes mellitus, otitis media, hepatitis, bronchitis gall stones, kidney stones, asthma and ischemic diseases. We call the gold coins a long cherry paste. It grows everywhere in our country, but it is common in the sunny and sunny areas.
여러해살이풀로 키는 5~25cm쯤 자라고 잎은 신장 모양으로 마주 난다. 꽃은 연한 보라색으로 6~8월에 피고 달고 단단한 열매는 9월에 익는다. 꽃에 꿀이 많아 벌들이 많이 모인다. 활혈단, 연전초 등의 다른 이름이 있다.The perennial plant grows about 5 ~ 25cm tall and the leaves face in kidney shape. The flowers are light purple and bloom in June-August, and hard berries ripen in September. There are a lot of honey in the flowers and a lot of bees gather. There are other names, such as the bow,
소변을 잘 보게 하고 황달을 고치며 몸이 붓는 것을 낫게 하는 작용이 있다. 열을 내리고 독을 풀며 염증을 삭이고 어혈을 없애는 효과도 있다. 또한 방광과 요도, 담낭의 결석을 녹이는 효과가 있으며 기침을 멎게 하고 가래를 삭이는 효과도 크다. 습진, 종기 같은 피부병에도 날 것을 짓찧어 붙이면 잘 낫는다.There is an action that makes urine look better, heals jaundice and heals body swelling. It also has the effect of lowering heat, poisoning, cutting inflammation and eliminating eosinophils. It also has the effect of dissolving bladder, urethra, and gall stones, and also has the effect of stopping coughing and shaving sputum. Eczema, boils and skin diseases, such as rashing things that are better if you stick.
상기 꼭두서니는 뿌리를 신경초라고 하여 민간에서 신경통, 관절염, 부종 황달치료에 쓴다. 신장과 방광의 결석을 녹이는데도 신기한 효과가 있다.The madder is called the nerve root of the roots and is used in the private for the treatment of neuralgia, arthritis, edema jaundice. It also has a remarkable effect in dissolving kidney and bladder stones.
우리나라 각지의 산과 들 마을 부근, 울타리 같은 곳에서 흔히 자라는데 길이가 2m쯤되고 줄기는 네모지며 잎은 심장 꼴로 돌아가며 난다. 줄기 속은 비어 있으나 뿌리는 통통하며 붉은 빛이 난다. 7~8월에 연한 노란색 꽃이 피어 9월에 까맣고 둥근 열매가 맺힌다.It grows frequently in the mountains, villages and fences of various parts of Korea. It grows about 2m in length, the stem is square, and the leaves turn back to the heart. The stem is empty but the root is plump and reddish. Light yellow flowers bloom from July to August, and black and round fruit is formed in September.
꼭두서니 뿌리는 신장과 방광의 결석을 녹이는 데 탁월한 효과가 있다. 꼭두서니 뿌리를 달인 물은 신장과 방광 결석을 천천히 부풀게 한 다음 녹여서 없앤다. 꼭두서니 뿌리에 있는 루베이트린산이라는 성분이 소변을 산성화하여 인산칼슘으로 된 결석을 녹이고 또 붉은색 색소 성분도 결석을 용해하는 작용을 한다.Madder roots have an excellent effect in dissolving stones in the kidneys and bladder. The water of the madder roots slowly inflates the kidney and bladder stones and melts them away. The ingredient, rubeitrin acid in the root of the madder, acidifies the urine to dissolve the calcium phosphate stones, and the red pigment ingredient dissolves the stones.
양혈, 행혈, 통경의 묘약으로 부인들의 생리불순, 자궁출혈, 적 백대하, 자궁내막염 등에 좋은 치료약이고 염증을 없애는 효력이 있어서 황달, 부종, 타박상, 만성기관지염 등에도 쓰인다. 또한 관절염에도 효과가 있고 이뇨작용이 있어 소변이 잘 안 나오는 데에도 쓰이며 기침을 멎게 하는 데에도 일정한 효과가 있다.It is a medicinal product of blood, blood and blood. It is a good remedy for the menstrual irregularities, uterine bleeding, infantile hemorrhage, and endometritis. It is also used for jaundice, swelling, bruise, and chronic bronchitis. It also has an effect on arthritis and diuretic action, which can be used to urinate poorly and has a certain effect on stopping coughing.
상기 할미꽃은 여러해살이 풀로서, 뿌리에 아네모닌과 탄닌질이 있다. 신선한 뿌리에는 프로토아네모닌의 형태로 들어있으며 공기 속에서 2분자가 중합되어 아네모닌으로 된다. 할미꽃(Pulsatilla koreana)은 다년생 초본으로 높이 40cm내외, 산지 건조한 개방지 초원에서 자라는 식물이다. 꽃은 4월 - 5월에 적자색으로 피고, 열매는 백색 털로 덮여 있으며 두통, 부종, 이질, 심장병, 학질, 위염 등에 약으로 쓴다. 특히 뇌질환을 치료하는 데 신통한 효과가 있는 것으로 알려져 있다. 할미꽃 뿌리를 잘 법제해서 사용하면 뇌종양을 비롯해 갖가지 암을 고칠 수 있다.It is a perennial plant, with anemone and tannin in its roots. Fresh roots contain protoanomonin in the form of two molecules in the air to become anemonin. Pulsatilla koreana (Pulsatilla koreana) is a perennial herb that grows about 40cm in height, and grows in mountainous, dry dogs. The flowers bloom in April-May with red purple, the fruit is covered with white fur, and it is used for headache, edema, dysentery, heart disease, schizophrenia and gastritis. It is known that there is a mystifying effect in treating brain diseases in particular. It is possible to fix various kinds of cancer including brain tumor by using lawful roots well.
상기 흰목이버섯(Tremella fuciformis)은 여름과 가을에 각종 활엽수의 죽은 나무 또는 나뭇가지에서 자란다. 자실체는 지름 3~8cm, 높이 2~5cm, 불규칙한 파형의 덩어리 모양 겹꽃 모양이다. 표면은 순백색, 평활하며, 자실층은 표면 전체에 발달한다. 조직은 반투명한 젤라틴질이다. 식용 버섯으로 면역 증진, 콜레스테롤 저하, 혈당강하, 항산화 작용이 있는 약용 버섯이며, 한방에서는 호흡기 질환, 위염, 고혈압, 월경 불순 등 여러 질환에 도움이 된다고 알려져 있다. 주요 성분으로는 비타민 B1, B2, D 및 니아신(niacin), 만니톨(mannitol), 글리세롤(glycerol), 글루코스(glucose), 트레할로스(trehalose), 헤미셀룰로우스(hemicellulose), 키틴(chitin), 펙틴(pectin), 루코노실로 만난(luconoxylomannan), 리그닌(lignin) 등이 알려져 있다.The above-mentioned Tremella fuciformis grows in various hardwood dead trees or branches in summer and autumn. Fruiting body is 3 ~ 8cm in diameter, 2 ~ 5cm in height, lumpy shape with irregular wave shape. The surface is pure white, smooth, and the fascial layer develops throughout the surface. The tissue is translucent gelatinous. It is medicinal mushroom which has immunity enhancement, cholesterol lowering, blood sugar lowering, antioxidant effect by edible mushroom, and it is known that it is helpful in various diseases such as respiratory diseases, gastritis, hypertension and menstrual irregularity. The main components include vitamins B1, B2, D and niacin, mannitol, glycerol, glucose, trehalose, hemicellulose, chitin, pectin, (pectin), luconoxylomannan, lignin, and the like are known.
수염가래꽃은 한의학에서 생약으로 사용되고 있는 약용식물로서 다양한 생리활성물질을 함유하고 있다. 수염가래꽃은 반변련, 반변란 또는 급해색이라고 불리며 국내에서는 중부 이남과 제주도에 분포하고 도랑이나 냇가, 논두렁의 습지에서 서식하고 있다. 수염가래꽃은 전통적으로 이뇨, 소염, 해독 등의 효능을 가지고 있으며 천식, 호흡곤란, 백일해, 악성종기, 습진, 외상출혈을 치료하는 약재로 사용되었다.Beard Phalaenopsis is a medicinal plant used as herbal medicine in Oriental medicine and contains various physiologically active substances. Beard spiny flowers are called semi-mature, semi-irregular, or hasty colors. They are found in central and southern Jeju-do in Korea and live in ditches, ditches, and wetlands of rice paddies. Beard spiny flowers have traditionally been used for the treatment of diarrhea, inflammation and detoxification and have been used as medicines for the treatment of asthma, dyspnea, pertussis, malignant boils, eczema, and traumatic hemorrhage.
상기 으름(Akebiae quinata Decne)은 으름덩굴과에 속하는 낙엽성 덩굴식물로, 전국 각지에서 자생한다. 한 나무에서 암꽃과 수꽃이 다른 모양으로 따로따로 피어 관상용으로 사용된다. 또한, 어린잎과 열매는 식용, 뿌리, 가지는 약용으로 쓰인다. 구체적으로 새순과 어린 줄기는 나물로 먹었고, 꽃은 말려두었다가 향수를 대신하여 사용되었다. 줄기의 삶은 물은 노란색이나 황갈색의 염료로 사용되었으며, 특히 소염성 이뇨제, 소변통, 요도염, 인후통, 정신신경안정제에 효능이 있어 약용으로도 중요하게 사용되었다. 뿌리, 껍질은 배뇨장애에 효능이 있으며, 열매는 이뇨제, 중풍, 관절염에 효능이 있다.Akebiae quinata Decne is a deciduous vine plant belonging to the genus Lepidoptera, and grows throughout the country. In one tree, female flowers and male flowers are used separately for different ornamental purposes. In addition, young leaves and fruit are used for edible, root and branch medicinal purposes. Specifically, the sprouts and young stems were eaten as herbs, and the flowers were dried and used instead of perfume. Stem boiled water was used as a yellow or yellowish dye, and was especially important for medicinal use because it has efficacy for anti-inflammatory diuretics, urinalysis, urethritis, sore throat, and psychotropic drugs. Roots and bark are effective for urination disorders, and fruits are effective for diuretics, paralysis, and arthritis.
상기 식물발효 효소액의 제조에 사용가능한 상기 젖산균은 락토바실루스속 젖산균(Lactobacillus sp.), 스트렙토코쿠스속 젖산균(Streptococcus sp.), 페디오코쿠스속 젖산균(Pediococcus sp.), 류코노스톡속 젖산균(Leuconostoc sp.), 비피도박테리움속 젖산균(Bifidobacterium sp.) 등일 수 있다.The lactic acid bacterium which can be used for the production of the plant fermentation enzyme solution is selected from the group consisting of Lactobacillus sp., Streptococcus sp., Pediococcus sp., Leuconostoc sp. Lactic acid bacteria Leuconostoc sp.), Bifidobacterium sp. (Bifidobacterium sp.), And the like.
또한, 상기 효모로는 사카로마이세스 세레비시아에(Saccharomyces sereviciae), 사카로마이세스 루시(Saccharomyces rouxii), 사카로마이세스 오비폴미스(Saccharomyces oviformis), 사카로마이세스 스테이네리(Saccharomyces steineri) 등이 사용될 수 있다.Examples of the yeast include Saccharomyces sereviciae, Saccharomyces rouxii, Saccharomyces oviformis, Saccharomyces steineri, Saccharomyces cerevisiae, ) May be used.
상기에서 당으로는 벌꿀과 설탕을 1~3 : 1~3 중량비로 혼합한 것이 사용될 수 있다.The saccharide may be a mixture of honey and sugar at a weight ratio of 1: 3: 1 ~ 3.
본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물은 그 자체로 건강기능식품 조성물로 사용될 수 있으며, 담체, 부형제 또는 희석제 등을 더 추가하여 다양한 형태로 제조될 수 있다. 상기 담체, 부형제 및 희석제로는 결정포도당, 트레할로스, 잔탄검, 아라비아검, 구아검, 탈지분유, 말토덱스트린, 젤라틴, 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 칼슘 포스페이트, 칼슘실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다.The composition for improving and preventing gastroesophageal reflux and gastritis according to the present invention may be used as a health functional food composition itself, and may be prepared in various forms by further adding a carrier, excipient or diluent. Examples of the carrier, excipient and diluent include crystalline glucose, trehalose, xanthan gum, gum arabic, guar gum, skim milk powder, maltodextrin, gelatin, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, The present invention relates to a method for producing a microcapsule comprising a microcapsule containing at least one selected from the group consisting of acacia rubber, alginate, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, .
상기 건강기능식품 조성물은 산제, 과립제, 환제 정제, 캡슐제, 현탁액, 에멀젼, 시럽제, 액제, 엑스제, 차, 젤리, 에어로졸, 음료 등의 형태로 제형화할 수 있다. The health functional food composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, solutions, expansions, tea, jellies, aerosols, drinks and the like.
상기 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. The health functional food composition may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
본 발명은 또한,The present invention also relates to
(a) 평균입자크기가 100 ∼ 300 메쉬인 옥분말 3~7 중량부, 로진 2~5 중량부, 프럭탄(Fructan) 2~5 중량부를 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 50~100 중량부에 혼합하는 단계; (a) 3 to 7 parts by weight of jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말과 혼합하여 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물의 제조방법에 관한 것이다. (e) mixing the crushed particles prepared in the step (d) with a jade powder having an average particle size of 100 to 300 mesh, and coating the jade powder on the surface. And a method for preparing the composition.
상기 역류성 식도염 및 위염 개선 및 예방용 조성물에서 전술된 내용은 그래도 상기 제조방법에 적용될 수 있다. 그러므로 중복된 내용은 생략한다.The above-mentioned contents in the composition for improving and preventing gastroesophageal reflux and gastritis can be applied to the above-described preparation method. Therefore, duplicate content is omitted.
본 발명에 있어서, 용어 "개선"은 역류성 식도염 및 위염 개선 및 예방용 조성물을 역류성 식도염을 가진 개체에게 투여, 섭취 또는 적용하여 역류성 식도염 증상의 경감, 예방 또는 치료를 포함하는 의미이다.In the present invention, the term " improvement "is meant to include alleviation, prevention or treatment of reflux esophagitis and gastritis symptom relief and prevention by administering, ingesting or applying to a subject having reflux esophagitis.
삭제delete
본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물의 복용량은 특별히 한정되지 않으나, 하루 복용량이 20g을 초과하지 않는 것이 바람직하며, 1회에 1~5 g씩을 물 없이 또는 물과 함께 자주 복용하는 것이 바람직하다.The dose of the composition for improving and preventing gastroesophageal reflux and gastritis of the present invention is not particularly limited, but it is preferable that the daily dose is not more than 20 g, and 1 to 5 g of the composition is administered at a time with or without water desirable.
이하, 본 발명을 실시예를 들어 더욱 상세히 설명하지만, 본 발명이 하기 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.
제조예Manufacturing example 1: 식물발효 1: Plant fermentation 효소액의Enzyme solution 제조 Produce
개별꽃 5 중량부, 은행 10 중량부, 고련피 5 중량부, 도라지 10 중량부, 금전초 5 중량부, 더덕 10 중량부, 꼭두서니 5 중량부, 할미꽃 5 중량부, 흰목이버섯 5 중량부, 잔대 10 중량부, 으름 10 중량부, 수염가래꽃 5 중량부, 움나무 10 중량부 및 그라비올라 잎 10 중량부를 씻어 건조된 항아리에 넣고, 미생물의 먹이가 될 수 있는 당으로서 벌꿀과 흑설탕을 1:1의 중량비로 상기 약초식물 100 중량부를 기준으로 20 중량부를 넣어주었다. 그 다음 Streptococcus sp.균주를 접종하고, 공기가 통할 수 있게 항아리를 봉하여 그늘에 보관하였다. 1개월에 1회씩 약초식물을 뒤집어 주면서 3개월 동안 발효시켰다. 그 다음 발효된 찌꺼기를 걸러서 짜낸 후, 9개월간 더 숙성시켜서 식물발효 효소액을 제조하였다. 5 parts by weight of individual flowers, 10 parts by weight of bank, 5 parts by weight of bellflower, 10 parts by weight of bellflower, 5 parts by weight of fennel, 10 parts by weight of fennel, 5 parts by weight of madder, 5 parts by weight of horticulture, 10 parts by weight of corn, 10 parts by weight of beeswax, 5 parts by weight of bean sprouts and 10 parts by weight of graviola leaves and 10 parts by weight of graviola leaves were placed in a dried jar and honey and brown sugar were mixed in a ratio of 1: 1 was added in an amount of 20 parts by weight based on 100 parts by weight of the herbaceous plant. Then, Streptococcus sp. Strain was inoculated, and the jar was sealed to allow air to pass through and stored in the shade. The herb plant was inverted once a month and fermented for 3 months. Then, the fermented residue was squeezed out and sieved for 9 months to prepare a plant fermentation enzyme solution.
실시예Example 1: 역류성 식도염 및 위염 개선 및 예방용 조성물 1: composition for improving and preventing reflux esophagitis and gastritis
가마솥에서 평균입자크기가 200메쉬인 연옥분말 150 g, 로진 150g, 및 프럭탄 150g을 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수로서 대일광업㈜ 제조 "(주)성민코리아" 10 리터와 잘 혼합하였다. 다음 가마솥을 100℃로 가열하면서 상기 혼합물을 잘 저어 주면서 수분을 증발시켰다. 수분이 증발된 혼합물을 급속 냉각시켜서 고체화시켰다. 상기에서 제조된 고체 조성물을 분쇄한 후, 상기 분쇄 고체 조성물에 상기 제조예 1에서 제조된 식물발효 효소액 500 ml를 분무하고 건조시켰다. 다음에 상기 건조된 분쇄 고체 조성물을 평균입자크기가 200메쉬인 연옥분말에 넣고 굴려서 표면에 연옥분말이 코팅된 역류성 식도염 및 위염 개선 및 예방용 조성물을 제조하였다. 150 g of nephrite powder having an average particle size of 200 mesh in a cauldron, 150 g of rosin, and 150 g of fructan were taken as a natural alkaline reducing water having a pH of 7.5 to 8.5, which was collected from Jade mine area and manufactured by Daeil Mining Co., . Next, while the cauldron was heated to 100 DEG C, the mixture was stirred and the water was evaporated. The water-evaporated mixture was solidified by rapid cooling. After the solid composition prepared above was pulverized, 500 ml of the plant fermentation enzyme solution prepared in Preparation Example 1 was sprayed on the pulverized solid composition and dried. Next, the dried pulverized solid composition was put into a nephrite powder having an average particle size of 200 mesh and rolled to prepare a composition for improving and preventing gastroesophageal reflux and gastritis, the surface of which was coated with nephrite powder.
시험예Test Example 1: 역류성 식도염 및 위염 개선 및 예방용 조성물의 효과 평가 1: Assessment of efficacy of compositions for improving and preventing gastroesophageal reflux and gastritis
역류성 식도염 증상이 있는 성인 남자 10명 여자 10명을 피험군으로 하여 상기 실시예 1에서 제조된 역류성 식도염 및 위염 개선 및 예방용 조성물을 1일 5회 1회당 1.5g씩 2~3 시간 간격으로 복용하게 하고, 복용후 10일, 20일, 30일에 역류성 식도염의 개선 정도를 평가하고, 그 결과를 하기 표 1에 나타내었다. 10 male and 10 female subjects with reflux esophagitis were selected as the experimental group. The composition for the improvement and prevention of gastroesophageal reflux and gastritis prepared in Example 1 was administered at intervals of 2 to 3 hours The degree of improvement of reflux esophagitis was evaluated at 10 days, 20 days and 30 days after administration, and the results are shown in Table 1 below.
<평가기준><Evaluation Criteria>
◎: 80% 개선됨◎: 80% improved
○: 50% 개선됨○: 50% improved
△: 20% 개선됨△: 20% improvement
×: 변화 없음X: No change
××: 악화됨××: worse
상기 표 1의 결과로부터 본 발명의 역류성 식도염 및 위염 개선 및 예방용 조성물을 복용한 피혐군들의 경우, 매우 우수한 역류성 식도염 및 위염 개선효과를 얻은 것으로 확인되었다. 또한, 부작용은 전혀 확인되지 않았다.From the results shown in the above Table 1, it was confirmed that the subjects receiving the reflux esophagitis and compositions for improving and preventing gastritis according to the present invention had excellent reflux esophagitis and gastritis improvement. No side effects were observed at all.
시험예Test Example 2: 동물모델에서의 급성 2: Acute in animal models 역류성식도염Reflux esophagitis 개선 효과 실험 Improvement effect experiment
특정 미네랄을 포함하고 있는 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수((주)성민코리아 제조, 닥터M)을 사용하여 역류성식도염 동물모델인 6주령의 Rat에 대하여 알칼리미네랄수가 역류성 식도염 증상의 개선에 미치는 효과 검증을 위한 임상시험을 진행하였다.Using alkaline reducing water (Doctor M, SungMin KOREA Co., Ltd., pH 7.5 ~ 8.5) collected from the jade mine area containing specific minerals, the alkaline mineral water for 6 - week - old Rat, an animal model of reflux esophagitis, Clinical trials were carried out to verify the effects of treatment on symptom improvement.
역류성식도염 동물모델은 6주령의 Rat를 공급받아 22±2℃, 습도 40±5%, 12시간-12시간(light-night)의 환경에서 1주간 적응 후 실험에 사용하였으며 각 Rat의 무게는 표 2에 나타내었다. 처리구는 Group 1(Normal, n=6), Group 2(RE Control, n=6), Group 3(닥터M), n=6) 로 나누어 진행하였으며, Group 1, 2는 7일간 수돗물을 공급하였고 Group 3는 닥터M을 공급하였다. 수술 전 18시간 동안 절식하여 실험에 이용하였으며 Group 1은 개복수술만 이루어졌고 Group 2, 3 처리구는 각각 수돗물, 닥터M을 경구투여 하였으며 1시간 30분 후 유문 및 전위부 결찰 뒤 봉합하였다. 수술 5시간 뒤 식도 조직을 분석하기 위해 개복하여 분리하였다. The reflux esophagitis animal model was used for the experiment after 1 week of adaptation in the environment of 22 ± 2 ℃,
(단위: g)(Unit: g)
(1) 손상도 측정(1) Measurement of damage degree
유문 및 전위부 결찰 수술 5시간 후, 식도를 분리하였고 수술용 가위를 이용하여 식도를 세로로 절단하였다. 절단된 식도 내부는 적당량의 0.9% NaCl로 세척하여 전개한 뒤 광학 디지털 카메라(Nicon)를 이용하여 촬영하였다. 손상된 식도점막 측정은 image J 프로그램을 이용하여 실제 손상부위의 면적을 측정하였다. 수술 전 수돗물을 급여하여 역류성식도염을 유발한 대조군(RE control)에서는 식도 점막이 위산에 의한 화학적 손상으로 발적, 충혈, 염증이 발생하였고 손상 부위 면적 비율은 47.1% 로 분석되었다. 닥터M을 7일간 급여 및 수술전 1회 경구투여 후 역류성식도염을 유발한 실험군에서는 9.21% 로 대조군에 비해 손상도가 효과적으로 감소됨을 확인하였다(도 1).After 5 hours of operation, the esophagus was removed and the esophagus was cut longitudinally using surgical scissors. The cut esophagus was rinsed with an appropriate amount of 0.9% NaCl and developed using an optical digital camera (Nicon). The damaged esophageal mucosa was measured using the image J program. In control group (RE control), which caused reflux esophagitis by feeding tap water before operation, esophageal mucosa was chemically damaged by stomach acid, resulting in redness, redness and inflammation. The area ratio of damage area was 47.1%. It was confirmed that the damage was effectively reduced in 9.21% of the experimental group which caused the reflux esophagitis after the 7-day administration and 1-oral administration of the doctor M (Fig. 1).
(2) 조직병리학적 검사(2) Histopathological examination
역류성식도염 발생에 대한 항염증 효과를 조직병리학적 검사로 확인하기 위해 H-E 염색을 실시하였다. 실험 종료 시점에서 실험동물을 호흡마취하고 조직을 적출하였으며, 조직을 10% neutral buffered formalin으로 고정하고 수세 후 ethanol과 xylene으로 탈수와 투명을 거쳐 파라핀에 포매하였다. 조직을 5㎛ 두께로 박절하여 hematoxylin과 eosin으로 일반적인 방법으로 염색하였고, 염색된 조직은 광학현미경(Leica DM 2500)으로 관찰하여 image analysis program(i-solution DT)으로 촬영 및 분석하였다역류성식도염을 유발하지 않은 군에서는 정상적인 점막 구조가 관찰되었으나, 역류성식도염 발생군에서는 식도 상피의 광범위한 탈락이 관찰되었다. 반면, 닥터M 투여군에서는 정상 조직과 유사한 식도 상피의 조직 구조를 유지하고 있었다(도 2).H-E staining was performed to confirm the anti-inflammatory effect on the development of reflux esophagitis by histopathological examination. At the end of the experiment, the animals were anesthetized with anesthesia and the tissues were extracted. The tissues were fixed with 10% neutral buffered formalin, and then embedded in paraffin through dehydration and transparency with ethanol and xylene. The tissue was stained with hematoxylin and eosin, and the stained tissue was observed with an optical microscope (Leica DM 2500). The tissue was photographed and analyzed with an image analysis program (i-solution DT) In the non-treated group, normal mucosal structure was observed, but in the case of reflux esophagitis, a wide range of esophageal epithelium disappeared. On the other hand, the doctor M administration group maintained the tissue structure of the esophageal epithelium similar to normal tissue (Fig. 2).
(3) (3) 염증유도단백질Inflammation-inducing protein iNOSiNOS 발현량 측정 Measurement of expression level
분리된 식도조직을 이용하여 Western blot을 통해 발현량을 측정하였다. 분리된 식도 조직에서 Buffer A를 이용하여 세포질을 분리한 후 BSA를 통해 단백질 정량 후 Blue-buffer 을 첨가하여 loading sample을 제조하였다. 각 Sample 은 running gel 과 stacking gel을 이용하여 120V에서 SDS-polyacrylamide gel 전기영동을 실시하였다. Transfer를 위해 membrane을 transbuffer를 이용하여 60분간 이동시켰고 5% skim-milk solution 으로 blocking 하였다. iNOS, b-actin 1차 항체는 4℃에서 18시간 이상 반응시켰고, 1X PBS로 3회 세척 후 실온에서 2차 항체를 2시간 반응시킨 후 1X PBS로 세척하였다. 세척된 membrane에 ECL detection kit 의 발색시약 Ⅰ,Ⅱ를 1:1로 혼합하여 도포하고 Chemidoc system(Bio-rad)을 이용하여 관찰하였다. 그 결과, 닥터M을 처리하였을 때 RE control 처리구에 비해 염증유도물질인 iNOS 발현량을 53% 억제함을 확인할 수 있었다(도 3).Expression levels were measured by Western blot using isolated esophageal tissue. In the isolated esophageal tissue, the cytoplasm was isolated using Buffer A, and the loading sample was prepared by adding Blue-buffer after quantification of the protein through BSA. Each sample was subjected to SDS-polyacrylamide gel electrophoresis at 120V using running gel and stacking gel. For transfer, membranes were transferred using a transbuffer for 60 minutes and blocked with 5% skim-milk solution. The iNOS and b-actin primary antibodies were reacted at 4 ° C for 18 hours or more, washed 3 times with 1X PBS, reacted with the secondary antibody for 2 hours at room temperature, and washed with 1X PBS. The washed membranes were mixed with ECL detection kit, coloring reagents Ⅰ and Ⅱ in a ratio of 1: 1, and observed using a Chemidoc system (Bio-Rad). As a result, it was confirmed that when Dr. M was treated, the amount of iNOS expression, which is an inflammation inducer, was reduced by 53% as compared with the RE control treatment (FIG. 3).
시험예Test Example 3: 동물모델에서의 급성 위염 개선 효과 실험 3: Experiments on the improvement of acute gastritis in animal models
역류성식도염 동물모델은 6주령의 mice를 공급받아 22±2℃, 습도 40±5%, 12시간-12시간(light-night)의 환경에서 1주간 적응 후 실험에 사용하였으며 각 mice의 무게는 표 3에 나타내었다. 처리구는 Group 1(Normal, n=6), Group 2(Control, n=6), Group 3(닥터M), n=6) 로 나누어 진행하였으며, Group 1, 2는 7일간 수돗물을 공급하였고 Group 3는 닥터M을 공급하였다. 수술 전 18시간 동안 절식하여 실험에 이용하였으며 Group 2, 3은 각각 수돗물과 닥터M을 경구투여 한 뒤 1시간 후에 위염 유발을 위해 300mM HCL+60% ethanol 을 경구투여 하였다. 1시간 뒤 위 조직 분석을 위해 경추탈골 후 개복하여 위 조직을 적출하였다.The reflux esophagus animal model was used for post-adaptation experiments at 22 ± 2 ° C,
(단위: g)(Unit: g)
(1) 손상도 측정(1) Measurement of damage degree
위염 유발 1시간 후 위 조직을 분리하였고 식도 내부는 적당량의 0.9% NaCl로 세척하여 전개한 뒤 광학 디지털 카메라(Nicon)를 이용하여 촬영하였다. 그 결과 일반생수를 급여한 뒤 위염을 유발한 처리군에 비해 닥터M을 급여한 뒤 위염을 유발하였을 때 조직 손상이 완화됨을 확인하였다(도 4).The stomach tissue was isolated 1 hour after gastritis induction. The inside of the esophagus was cleaned with an appropriate amount of 0.9% NaCl and developed using an optical digital camera (Nicon). As a result, it was confirmed that tissue damage was alleviated when Doctor M was fed and gastritis was induced compared to the treatment group in which general water was fed and then gastritis was induced (FIG. 4).
(2) 조직병리학적 검사(2) Histopathological examination
위염 발생에 대한 항염증 효과를 조직병리학적 검사로 확인하기 위해 H-E 염색을 실시하였다. 실험 종료 시점에서 실험동물을 호흡마취하고 조직을 적출하였으며, 조직을 10% neutral buffered formalin으로 고정하고 수세 후 ethanol과 xylene으로 탈수와 투명을 거쳐 파라핀에 포매하였다. 조직을 5㎛ 두께로 박절하여 hematoxylin과 eosin으로 일반적인 방법으로 염색하였고, 염색된 조직은 광학현미경(Leica DM 2500)으로 관찰하여 image analysis program(i-solution DT)으로 촬영 및 분석하였다. 위염을 유발하지 않은 군에서는 정상적인 점막 구조가 관찰되었으나, HCl/EtOH 처리를 통하 위염 발생군에서는 점막과 점막아래 영역에서 염증세포의 침착과 심각한 점막상피 세포의 탈락이 관찰되었다. 반면 닥터M 투여군에서는 HCl/EtOH처리에 의한 염증 유발이 억제됨을 확인하였으며 점막 부위 염증세포 침착이나 점막상피 세포의 탈락이 HCl/EtOH 단독 처리 군과 비교해서 정상 조직에 가까운 조직 구조가 관찰되었다(도 5).H-E staining was performed to confirm the anti-inflammatory effect of gastritis by histopathological examination. At the end of the experiment, the animals were anesthetized with anesthesia and the tissues were extracted. The tissues were fixed with 10% neutral buffered formalin, and then embedded in paraffin through dehydration and transparency with ethanol and xylene. The tissue was stained with hematoxylin and eosin at 5 μm thickness. The stained tissue was observed with an optical microscope (Leica DM 2500) and analyzed with an image analysis program (i-solution DT). In the gastritis group, normal mucous membrane structure was observed, however, inflammatory cell deposition and severe mucosal epithelial cell disappeared in the mucosa and submucosa in the gastritis group treated with HCl / EtOH. On the other hand, it was confirmed that the induction of inflammation by HCl / EtOH treatment was inhibited in the M-treated group, and the morphological inflammatory cell deposition or mucosal epithelial cell disappeared was observed in the tissue structure close to the normal tissue as compared with the HCl / EtOH alone treatment group 5).
(3) (3) 염증유도단백질Inflammation-inducing protein iNOSiNOS 발현량 측정 Measurement of expression level
분리된 위 조직을 이용하여 Western blot 을 통해 발현량을 측정하였다. 분리된 위 조직에서 Buffer A를 이용하여 세포질을 분리한 후 BSA를 통해 단백질 정량 후 Blue-buffer 을 첨가하여 loading sample을 제조하였다. 각 Sample 은 running gel 과 stacking gel을 이용하여 120V에서 SDS-polyacrylamide gel 전기영동을 실시하였다. Transfer를 위해 membrane을 transbuffer를 이용하여 60분간 이동시켰고 5% skim-milk solution 으로 blocking 하였다. iNOS, b-actin 1차 항체는 4℃에서 18시간 이상 반응시켰고, 1X PBS로 3회 세척 후 실온에서 2차 항체를 2시간 반응시킨 후 1X PBS로 세척하였다. 세척된 membrane에 ECL detection kit 의 발색시약 Ⅰ,Ⅱ를 1:1로 혼합하여 도포하고 Chemidoc system(Bio-rad)을 이용하여 관찰하였다. 그 결과, 일반생수를 급여한 뒤 위염을 유발한 처리구에 비해 닥터M을 급여한 후 위염을 유발하였을 때 염증유도물질인 iNOS 발현량이 14% 억제됨을 확인하였다(도 6).The expression level was measured by Western blot using the isolated stomach tissue. After separating the cytoplasm using Buffer A in the isolated stomach, the protein was quantitated by BSA and then added with Blue-buffer to prepare a loading sample. Each sample was subjected to SDS-polyacrylamide gel electrophoresis at 120V using running gel and stacking gel. For transfer, membranes were transferred using a transbuffer for 60 minutes and blocked with 5% skim-milk solution. The iNOS and b-actin primary antibodies were reacted at 4 ° C for 18 hours or more, washed 3 times with 1X PBS, reacted with the secondary antibody for 2 hours at room temperature, and washed with 1X PBS. The washed membranes were mixed with ECL detection kit, coloring reagents Ⅰ and Ⅱ in a ratio of 1: 1, and observed using a Chemidoc system (Bio-Rad). As a result, it was confirmed that the amount of iNOS expression, which is an inflammation inducer, was inhibited by 14% when Drug M was fed and gastritis was induced as compared to the treatment which induced gastritis after feeding with ordinary water (Fig. 6).
시험예Test Example 4: 4: 역류성식도염Reflux esophagitis 개선 효과 임상시험 Improvement clinical trial
(1) 실험 개요(1) Outline of experiment
본 연구에서는 특정 미네랄을 포함하고 있는 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수(닥터M)을 역류성 식도염 환자에게 음용하게 함으로써 알칼리미네랄수가 역류성 식도염 증상의 개선에 미치는 효과 검증을 위한 임상시험을 진행하였다.The purpose of this study was to evaluate the effect of alkaline mineral water on the improvement of symptoms of reflux esophagitis by drinking the natural alkaline reducing water (Doctor M) at pH 7.5 ~ 8.5 collected from the jade mine area containing specific minerals in patients with reflux esophagitis The test was conducted.
(2) 임상시험 방법(2) Clinical test method
2017년 3월부터 2017년 7월까지 병원(박가정의학과 의원, 인천광역시 부평구 소재)에 내원한 환자로서 위내시경 검사에서 역류성 식도염 진단을 받은 환자를 대상으로 임상시험을 진행하였다.From March 2017 to July 2017, a clinical examination was conducted in a patient who had been diagnosed with gastroesophageal reflux disease (gastroscopy) at a hospital (Park, Gapjung Medical Center, Bupyeong-gu, Incheon).
a. 실험 전 임상연구에 대한 충분할 설명을 하며 각 참여자에게 임상시험 동의서를 받았다.a. A sufficient explanation for the pre-experiment clinical study was given and each participant received the clinical trial consent.
b. 성인 1인 1일 15ml/kg의 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수(닥터M)를 음용하게 하였다.b. Natural alkaline-reduced water (Dr. M), pH 7.5-8.5, collected in the jade mine area of 15ml / kg per adult per day was drunk.
c. 음용기간은 2개월로 하며 환자의 상태와 임상연구 호응도에 따라 기간 조정이 가능한 것으로 하였다.c. The duration of drinking was 2 months, and the duration was adjusted according to the patient 's condition and clinical response.
d. 임상시험 기간 동안 주기적으로 병원을 방문하여 경과를 평가하며 6개월간 내원한 환자 중 연구 대상자를 선정하였다.d. During the study period, the patients visited the hospital periodically and evaluated their progress.
e. 임상시험 기간 동안 다른 약물 복용을 금하는 것을 원칙으로 하며 환자의 사정상 필요시 약물을 지급할 수도 있는 것으로 하였다.e. It is the principle to prohibit the use of other medications during the clinical trial period, and the drug may be paid if necessary for the convenience of the patient.
f. 기타 평상시의 생활습관을 유지하고 복용하고 있는 약이 있다면 그대로 복용하도록 하였다.f. If you have any other medication you are taking and keep your usual lifestyle, take it as is.
g. 시작 전 그리고 음용 2-4개월 후 내시경을 시행하여 경과를 평가하였다.g. Endoscopy was performed before and 2 to 4 months after the operation to evaluate progress.
h. 조사표를 만들어 환자들의 상태를 체크하고 2개월 후 결과를 정리하고 실험전과 비교하여 효과를 확인하였다.h. A questionnaire was made to check the patients' condition and after 2 months, the results were summarized and compared with those before the experiment.
(3) 임상시험 결과(3) Clinical test results
개별적인 임상시험 결과는 도 7 내지 30에 나타내었으며, 종합적인 임상결과는 도 31에 나타내었다. The results of individual clinical studies are shown in FIGS. 7 to 30, and the comprehensive clinical results are shown in FIG.
상기 도 7 내지 30 및 도 31에서 확인되는 바와 같이, 특별한 미네랄을 함유하고 있는 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수(닥터M)는 역류성 식도염에 매우 우수한 효과를 나타냄을 확인할 수 있다. 즉 임상시험 참가자의 93%가 효과가 있는 것으로 평가하였으며, 72%는 매우 우수한 효과가 있는 것으로 평가하였다. As can be seen from FIGS. 7 to 30 and FIG. 31, it was confirmed that the natural alkali reduced water (Doctor M) having a pH of 7.5 to 8.5, which was collected in the jade mine area containing special minerals, showed a very excellent effect on the reflux esophagitis have. That is, 93% of the participants in the clinical trial were evaluated as effective, and 72% of the participants were evaluated as having a very good effect.
특히, 기존 약물과 비교하는 경우에도 임상시험 참가자의 78%가 약물과 동등 이상의 효과를 제공하는 것으로 평가하였으며, 57%는 약물보다 더 우수한 것으로 평가하였다. In particular, even when compared with existing drugs, 78% of the participants in the study were evaluated to be equivalent to the drug, and 57% were evaluated as superior to the drug.
Claims (5)
(a) 평균입자크기가 100 ∼ 300 메쉬인 옥분말 3~7 중량부, 로진 2~5 중량부, 프럭탄(Fructan) 2~5 중량부를 옥광산 지역에서 채취한 pH 7.5~8.5의 천연 알칼리환원수 50~100 중량부에 혼합하는 단계;
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말에 넣어 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물.Rosin, fructan, and vegetable fermentation enzyme solution contained in natural alkaline reducing water of pH 7.5 to 8.5, which is collected from the jade powder and jade mine area,
(a) 3 to 7 parts by weight of jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) coating the surface of the ground particles prepared in the step (d) with a powder of jade powder having an average particle size of 100 to 300 mesh, thereby improving and preventing reflux esophagitis and gastritis. / RTI >
상기 옥분말은 연옥분말인 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물.The method according to claim 1,
Wherein the jade powder is a nephrite powder.
상기 식물발효 효소액은
(ⅰ) 개별꽃 1~10 중량부, 은행 1~20 중량부, 고련피 1~10 중량부, 도라지 1~20 중량부, 금전초 1~10 중량부, 더덕 1~20 중량부, 꼭두서니 1~10 중량부, 할미꽃 1~10 중량부, 흰목이버섯 1~10 중량부, 잔대 1~20 중량부, 으름 1~20 중량부, 수염가래꽃 1~10 중량부, 움나무 1~20 중량부 및 그라비올라 잎 1~20 중량부를 포함하는 약초 식물을 씻어 물을 빼는 단계;
(ⅱ) 상기 (ⅰ)단계에서 씻은 약초 식물을 항아리에 넣고, 미생물의 먹이가 될 수 있는 당을 상기 식물 100 중량부를 기준으로 10~30 중량부로 넣고, 젖산균 및 효모 중의 1종 이상의 균주를 접종하여 20~40℃에서 1~4개월 동안 발효시키는 단계;
(ⅲ) 발효된 찌꺼기를 걸러서 짜낸 후, 1~10개월 숙성시키는 단계;를 포함하는 방법에 의해 제조되는 것임을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물.The method according to claim 1,
The plant fermentation enzyme solution
(I) 1 to 10 parts by weight of an individual flower, 1 to 20 parts by weight of a bank, 1 to 10 parts by weight of spinach, 1 to 20 parts by weight of bellflower, 1 to 10 parts by weight of fennel, 1 to 20 parts by weight of fennel, 1 to 10 parts by weight of hymenoptera, 1 to 10 parts by weight of white chestnut mushroom, 1 to 20 parts by weight of cornstarch, 1 to 20 parts by weight of crumbs, 1 to 10 parts by weight of bean sprout flowers, 1 to 20 parts by weight And 1 to 20 parts by weight of graviola leaves;
(Ii) The herbaceous plant washed in step (i) is placed in a jar and 10 to 30 parts by weight of sugar capable of being fed to the microorganism is added in an amount of 10 to 30 parts by weight based on 100 parts by weight of the plant, and one or more strains of lactic acid bacteria and yeast are inoculated Followed by fermentation at 20 to 40 ° C for 1 to 4 months;
(Iii) squeezing out the fermented sludge, and aging the sludge for 1 to 10 months. The composition for improving and preventing gastritis of reflux esophagitis and gastritis.
상기 역류성 식도염 및 위염 개선 및 예방용 조성물은 건강기능식품인 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물.The method according to claim 1,
Wherein the composition for improving and preventing gastroesophageal reflux and gastritis is a health functional food.
(b) 상기 (a)단계에서 제조된 혼합물을 50~120℃로 교반하면서 가열하여 혼합 용융물을 제조하고, 물을 증발시키는 단계;
(c) 상기 물이 제거된 혼합물을 급속 냉동시켜 분쇄하는 단계;
(d) 상기 (c)단계에서 분쇄된 입자들에 식물발효 효소액을 분사하는 단계; 및
(e) 상기 (d)단계에서 제조된 분쇄 입자들을 평균입자크기가 100 ∼ 300 메쉬인 옥분말과 혼합하여 표면에 옥분말을 코팅하는 단계;를 포함하는 것을 특징으로 하는 역류성 식도염 및 위염 개선 및 예방용 조성물의 제조방법.(a) 3 to 7 parts by weight of a jade powder having an average particle size of 100 to 300 mesh, 2 to 5 parts by weight of rosin and 2 to 5 parts by weight of fructan are mixed with a natural alkali having a pH of 7.5 to 8.5 To 50 to 100 parts by weight of reduced water;
(b) heating the mixture prepared in step (a) at 50 to 120 DEG C with stirring to prepare a mixed melt, and evaporating water;
(c) rapidly freezing and pulverizing the mixture from which the water has been removed;
(d) spraying a plant fermentation enzyme solution onto the ground particles in the step (c); And
(e) mixing the crushed particles prepared in the step (d) with a jade powder having an average particle size of 100 to 300 mesh, and coating the jade powder on the surface. Gt;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170149617A KR101862742B1 (en) | 2017-11-10 | 2017-11-10 | Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170149617A KR101862742B1 (en) | 2017-11-10 | 2017-11-10 | Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101862742B1 true KR101862742B1 (en) | 2018-05-30 |
Family
ID=62300002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170149617A KR101862742B1 (en) | 2017-11-10 | 2017-11-10 | Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101862742B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102249840B1 (en) * | 2020-06-23 | 2021-05-10 | 이실구 | dried strips of sweet potatoes comprising collagen and manufacturing method thereof |
-
2017
- 2017-11-10 KR KR1020170149617A patent/KR101862742B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
산야초 효소 만들기 (다음 블로그, http://blog.daum.net/ps1740/9553498) (2006.10.04.) |
역류성식도염 증상과 한의원 치료 (네이버 블로그, http://blog.naver.com/idealja/110163849280) (2013.03.23.) |
자연의선물 옥샘 생수 리뷰! (네이버 블로그, http://blog.naver.com/hminana/220728593653) (2016.06.06.) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102249840B1 (en) * | 2020-06-23 | 2021-05-10 | 이실구 | dried strips of sweet potatoes comprising collagen and manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bakhru | Herbs that heal: natural remedies for good health | |
KR101176590B1 (en) | Herbal Composition for Removing Hangover and Beverage Containing the Same | |
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
Guarino et al. | Ethnobotanical study of the Sannio area, Campania, southern Italy | |
KR100976816B1 (en) | Composition for solving hangover and improving bowel and kidney function, and process for preparing the same | |
KR20180037693A (en) | A food composition for preventing and improving lung diseases | |
CN102871100B (en) | Ginger, bamboo and salt composition and preparation method thereof | |
CN102397524A (en) | Composition for protecting gastric mucosa, nourishing stomach and protecting stomach and preparation method thereof | |
CN107156828A (en) | A kind of full nutrition formula food suitable for patients with inflammatory bowel | |
CN106858215A (en) | A kind of passion fruit composite beverage | |
US20160199427A1 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
KR20140097961A (en) | Beverage for curing of hangover | |
KR100968674B1 (en) | Herbal composition for alcoholic hangover | |
KR101632794B1 (en) | METHOD OF MANUFACTURING PILL COMPRISED OF Protaetia brevitarsis seulensis | |
KR101224196B1 (en) | Method for omega-3 of crude drug and containing extracts hippophae rhamnoides l. | |
CN108635461A (en) | Dry eyes atomized liquid | |
KR101862742B1 (en) | Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same | |
KR20170057532A (en) | Composition for body temperature rise with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
CN105168799B (en) | A kind of drug and preparation method thereof for treating white diarrhea | |
CN104757242B (en) | It is a kind of to treat health-care sweets of chronic gastroenteropathy and preparation method thereof | |
US9895406B2 (en) | Homeopathic remedies and methods for enhancing weight loss | |
KR20160147424A (en) | An enzyme composition for treating metabolic disorders including extracts wasong | |
KR20090024033A (en) | Health assistant food and thereof manufacturing method | |
KR101297918B1 (en) | Obesity treatment composition and method of manufacturing the obesity treatment composition | |
CN105124076A (en) | Healthy tea capable of moistening throat and preparing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |